Clearbridge Investments LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 35.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 131,144 shares of the biopharmaceutical company's stock after selling 71,176 shares during the quarter. Clearbridge Investments LLC's holdings in Pfizer were worth $3,456,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. Bcwm LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $4,264,000. United Bank increased its holdings in Pfizer by 27.3% during the 4th quarter. United Bank now owns 45,331 shares of the biopharmaceutical company's stock worth $1,203,000 after acquiring an additional 9,732 shares during the period. Life Planning Partners Inc purchased a new stake in Pfizer in the 4th quarter worth approximately $893,000. Summit Securities Group LLC boosted its holdings in Pfizer by 38.4% in the 4th quarter. Summit Securities Group LLC now owns 23,800 shares of the biopharmaceutical company's stock valued at $631,000 after purchasing an additional 6,600 shares during the period. Finally, Schroder Investment Management Group grew its position in shares of Pfizer by 13.6% during the 4th quarter. Schroder Investment Management Group now owns 9,973,310 shares of the biopharmaceutical company's stock valued at $264,592,000 after purchasing an additional 1,193,722 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Trading Down 5.4 %
Pfizer stock traded down $1.30 during trading hours on Friday, reaching $22.99. The company had a trading volume of 79,829,399 shares, compared to its average volume of 39,462,795. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $22.91 and a 12-month high of $31.54. The company has a 50-day moving average price of $25.93 and a 200 day moving average price of $26.81. The firm has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
Insider Buying and Selling
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
PFE has been the subject of several research analyst reports. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America reiterated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.
Check Out Our Latest Analysis on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
